Haematology Laboratory, Nancy Academic Hospital, Nancy, France.
CNRS, Inria, LORIA, Lorraine University, Nancy, France.
Int J Lab Hematol. 2019 Dec;41(6):726-730. doi: 10.1111/ijlh.13094. Epub 2019 Sep 15.
The confirmation time interval for the presence of antiphospholipid antibodies (aPL) has been extended to 12 weeks as epiphenomenal antibodies may disappear after 6 weeks. Our aim was to analyse extended persistence of aPL positivity beyond the 12-week interval.
We retrospectively analysed our database of 23 856 aPL test samples collected between 2005 and 2017 from 17 367 consecutive patients. Two groups of patients were identified among aPL-positive patients, confirmed at 12 weeks: with or without extended persistence beyond confirmatory testing. Percentages of extended persistence are given according to the initial aPL positivity profiles, and baseline laboratory variables are compared between the two groups.
Three hundred and twenty-seven patients confirmed aPL-positive had subsequent testing. The vast majority of them displayed extended persistence in the long term: 89.6% and up to 97.9% for patients with initial triple positivity. In extended persistent positive patients, there were more LA-positive initial samples, and baseline LA test values and IgG aCL titres were higher than in nonpersistent positive patients.
Data from a large database of an aPL referral laboratory showed that the time interval of 12 weeks defining persistence of aPL positivity was appropriate for the majority of patients. Furthermore, we found baseline features associated with extended persistence.
抗磷脂抗体(aPL)的确认时间间隔已延长至 12 周,因为在 6 周后可能会消失偶发抗体。我们的目的是分析超过 12 周间隔后 aPL 阳性的持续延长。
我们回顾性分析了 2005 年至 2017 年间从 17367 例连续患者中收集的 23856 例 aPL 检测样本的数据库。在 12 周时确认的 aPL 阳性患者中,确定了两组患者:有或没有超出确认检测的持续延长。根据初始 aPL 阳性谱给出了持续延长的百分比,并比较了两组之间的基线实验室变量。
327 例确认 aPL 阳性的患者随后进行了检测。他们中的绝大多数在长期内表现出持续延长:初始三阳性患者的比例高达 89.6%,甚至高达 97.9%。在持续延长的阳性患者中,LA 阳性的初始样本更多,基线 LA 检测值和 IgG aCL 滴度高于非持续阳性患者。
来自 aPL 参考实验室的大型数据库的数据表明,将 12 周的时间间隔定义为 aPL 阳性持续时间的标准适用于大多数患者。此外,我们发现了与持续延长相关的基线特征。